Differential retinoic acid signaling in tumors of long- and short-term glioblastoma survivors

Journal of the National Cancer Institute

Volumn 103, Issue 7, 2011, Pages 598-601

  Barbus, Sebastian ^a   Tews, Björn ^a,b   Karra, Daniela ^c   Hahn, Meinhard ^a   Radlwimmer, Bernhard ^a   Delhomme, Nicolas ^a   Hartmann, Christian ^d   Felsberg, Jörg ^c   Krex, Dietmar ^e   Schackert, Gabriele ^e   Martinez, Ramon ^f   Reifenberger, Guido ^c   Lichter, Peter ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^f UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID BINDING PROTEIN; MESSENGER RNA; ONCOPROTEIN; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; RETINOIC ACID; RETINOIC ACID BINDING PROTEIN;

ARTICLE; CANCER SURVIVAL; CANCER SURVIVOR; CELL PROLIFERATION; ENZYME ACTIVATION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SURVIVAL TIME;

ADULT; AGED; BRAIN NEOPLASMS; COMPARATIVE GENOMIC HYBRIDIZATION; ENZYME ACTIVATION; FATTY ACID-BINDING PROTEINS; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROTEIN ARRAY ANALYSIS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, RETINOIC ACID; RNA, MESSENGER; SIGNAL TRANSDUCTION; SURVIVORS; TIME FACTORS; TRETINOIN;

EID: 79953836749     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr036     Document Type: Article

References (22)

1. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classifcation of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97-109. (Pubitemid 47103521)
2. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligoden-droglial gliomas. J Neuropathol Exp Neurol. 2005;64(6):479-489. (Pubitemid 40781150)
3. Krex D, Klink B, Hartmann C, et al. Long-term survival with glioblastoma multiforme. Brain. 2007;130(pt 10):2596-2606. (Pubitemid 47511715)
4. Martinez R, Schackert G, Yaya-Tur R, Rojas-Marcos I, Herman JG, Esteller M. Frequent hypermethylation of the DNA repair gene MGMT in long-term survivors of glioblas-toma multiforme. J Neurooncol. 2007;83(1): 91-93. (Pubitemid 46647170)
5. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glio-blastoma multiforme. Science. 2008;321(5897): 1807-1812.
6. Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009;27(25):4150-4154.
7. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765-773.
8. Karnofsky DA, Burchenal JH. The Clinical Evaluation of Chemotherapeutic Agents in Cancer., New York: Columbia University Press; 1949:196.
9. Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma. A prospective transla-tional study of the German Glioma Network. J Clin Oncol. 2009;27(34):5743-5750.
10. Schug TT, Berry DC, Shaw NS, Travis SN, Noy N. Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors. Cell. 2007; 129(4):723-733. (Pubitemid 46802374)
11. Ghyselinck NB, Bavik C, Sapin V, et al. Cellular retinol-binding protein I is essential for vitamin A homeostasis. EMBO J. 1999; 18(18):4903-4914. (Pubitemid 29443793)
12. Laudet V, Gronemeyer H. The Nuclear Receptor FactsBook., London: Academic Press; 2002.
13. Park DJ, Chumakov AM, Vuong PT, et al. CCAAT/enhancer binding protein epsilon is a potential retinoid target gene in acute promy-elocytic leukemia treatment. J Clin Invest. 1999;103(10):1399-1408. (Pubitemid 29535496)
14. Donato LJ, Suh JH, Noy N. Suppression of mammary carcinoma cell growth by retinoic acid: the cell cycle control gene Btg2 is a direct target for retinoic acid receptor signaling. Cancer Res. 2007;67(2):609-615. (Pubitemid 46192199)
15. Altucci L, Rossin A, Raffelsberger W, Reitmair A, Chomienne C, Gronemeyer H. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat Med. 2001;7(6):680-686. (Pubitemid 32588023)
16. Kitareewan S, Pitha-Rowe I, Sekula D, et al. UBE1L is a retinoid target that triggers PML/ RARalpha degradation and apoptosis in acute promyelocytic leukemia. Proc Natl Acad Sci USA. 2002;99(6):3806-3811. (Pubitemid 34252187)
17. Dudek H, Datta SR, Franke TF, et al. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science. 1997;275(5300):661-665. (Pubitemid 27061332)
18. Kawauchi K, Ogasawara T, Yasuyama M, Otsuka K, Yamada O. The PI3K/Akt pathway as a target in the treatment of hematologic malignancies. Anticancer Agents Med Chem. 2009;9(5):550-559.
19. Tari AM, Lim SJ, Hung MC, Esteva FJ, Lopez-Berestein G. Her2/neu induces all-trans retinoic acid (ATRA) resistance in breast cancer cells. Oncogene. 2002;21(34):5224-5232. (Pubitemid 34948134)
20. Verma AK. The differential effects of retinoic acid and 7,8-benzofavone on the induction of mouse skin tumors by the initiation-promotion protocol and by the complete carcinogenesis process. Carcinog Compr Surv. 1982;7:35-39.
21. Defer GL, Adle-Biassette H, Ricolf F, et al. All-trans retinoic acid in relapsing malignant gliomas: clinical and radiological stabilization associated with the appearance of intratumoral calcifcations. J Neurooncol. 1997;34(2):169-177. 22. (Pubitemid 27271723)
22. Yung WK, Kyritsis AP, Gleason MJ, Levin VA. Treatment of recurrent malignant gli-omas with high-dose 13-cis-retinoic acid. Clin Cancer Res. 1996;2(12):1931-1935. (Pubitemid 27006624)